Table 1

Baseline characteristics of new users

Cyproterone acetate/ethinylestradiolDrospirenone/ethinylestradiol
Characteristic2002201020022010
NaïveNon-naïveNaïveNon-naïveNaïveNon-naïveNaïveNon-naïve
679 (42.6)916 (57.4)797 (49.8)802 (50.2)95 (9.4)914 (90.6)649 (19.2)2724 (80.8)
Mean age (years) (95% CI)20.7 (20.2–21.3)25.5 (25.0–26.0)18.2* (17.8–18.6)23.3* (22.9–23.8)23.4 (21.7–25.2)27.6 (27.1–28.1)18.7* (18.3–19.2)24.3* (24.0–24.6)
Age at prescription (years)
12–19450 (66.3)236 (25.8)618 (77.5)292 (36.4)46 (48.4)155 (17.0)498 (76.7)894 (32.8)
20–29111 (16.3)389 (42.5)137 (17.2)363 (45.3)23 (24.2)396 (43.3)111 (17.1)1198 (44.0)
30–3996 (14.1)262 (28.6)33 (4.1)127 (15.8)22 (23.2)300 (32.8)26 (4.0)521 (19.1)
40–4922 (3.2)29 (3.2)9 (1.1)20 (2.5)4 (4.2)63 (6.9)14 (2.2)111 (4.1)
Levonorgestrel/ethinylestradiol
Characteristic20022010
NaïveNon-naïveNaïveNon-naïve
3946 (70.1)1686 (29.9)7157 (74.3)2476 (25.7)
Mean age (years) (95% CI)20.7 (20.4–20.9)27.3 (27.0–27.7)18.1* (18.0–18.2)24.9* (24.5–25.2)
Age at prescription (years)
12–192616 (66.3)384 (22.8)5759 (80.5)926 (37.4)
20–29713 (18.1)619 (36.7)1028 (14.4)816 (33.0)
30–39462 (11.7)542 (32.1)261 (3.6)552 (22.3)
40–49155 (3.9)141 (8.4)109 (1.5)182 (7.4)
  • *p<0.0001 vs 2002.

  • Data are n (%) unless stated otherwise.

  • CI, confidence interval.